This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Secukinumab for moderate to severe plaque psoriasis in children aged 6 to less than 18 years old

< Back

Secukinumab for moderate to severe plaque psoriasis in children aged 6 to less than 18 years old


Skin Disease, Burns and Wound Care

May 2019

Secukinumab as subcutaneous injection is in clinical development for the treatment of chronic plaque psoriasis in children and adolescents. Plaque psoriasis, is the most common type of psoriasis and is an inflammatory skin disease that typically follows a relapsing and remitting course. Plaque psoriasis is characterised by dry red skin lesions (called plaques) covered in silver scales which commonly appear on the elbows, knees, scalp and lower back. The plaques can be itchy and sore and in severe cases the skin may crack and bleed.
Secukinumab is a monoclonal antibody, a type of protein, designed to recognise and attach to a messenger molecule in the immune system called interleukin 17A. This molecule is involved in the inflammation and other immune system processes that cause psoriasis. By attaching to and blocking the action of interleukin 17A, secukinumab reduces the activity of the immune system and the symptoms of the disease. If licensed, secukinumab will offer a first-line systemic treatment option in children and adolescents with moderate to severe plaque psoriasis in patients who are candidates for systemic therapy.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts